In addition to GLP-1R agonists, orally administrated DPP4-inhibitors, e.g., sitagliptin and saxagliptin , which are known to potentiate the effect of endogenous GLP-1 by inhibiting its degradation, have also been clinically studied as protective agents against retinopathy (Svenningsson et al., 2016) in T2D patients, although DPP4-inhibitors cannot cross the blood-brain barrier (Mousa and Ayoub, 2019)
Our Experience At Rheumatologist OnCall, in the past two years, our patients have experienced: Remarkable drops in pain, morning stiffness (even with microdoses) Surge in energy, improved sleep, and confidence Steady, sustainable weight loss Reduced need for or the ability to taper steroids, DMARDs, and biologics For carefully selected patients, GLP-1 therapy has been truly life-changing
Rights and permissions About this article Cite this article Zhang, WQ., Wang, YJ., Zhang, A
Its no secret that GLP-1 medications like Ozempic, Wegovy, and Saxenda have become increasingly popular for weight loss
It focused on how this compound affects the connection between the gut and the brain, based on findings from three recent animal studies
